Britain and America have signed a landmark trade agreement that will guarantee zero duties on UK medicine products being sold in the American market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has agreed to boost expenditure on medicines through the National Health Service (NHS). This move guarantees that import taxes on these key goods will remain at nothing for a timeframe of three years.
This development follows earlier warnings to dramatically increase duties on branded pharmaceutical products, with figures mentioned reaching 100%.
"This deal with the Britain strengthens the global environment for innovative medicines and introduces long-overdue fairness to American-British pharmaceutical trade," a release declared.
Economic Impact
Pharmaceuticals constitute one of the the United Kingdom's largest export categories to the United States, which is by far the biggest buyer for large companies like GSK and AstraZeneca.
Export figures reveal that in the year leading up to last September, the UK shipped medicines totaling £11.1bn to the US. This value represented nearly one-fifth of British export trade in that timeframe.
"This agreement secures jobs, boosts investment and sets the stage for the UK to emerge as a worldwide center for life sciences," a government official stated.
Specific NHS Changes
The agreement entails several key changes from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it judges new medicines to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a target to increase overall NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The percentage drug companies must return to the NHS to stay within budget will be restricted at 15%. Previously, repayments topped 20%.
Recent Tensions
The pact takes place against a long-running row between the pharmaceutical industry and the ministers over spending levels and approval rates.
These tensions were heightened by assertions that US customers were paying a premium for the identical medicines than people in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been halted or scrapped, while major funding commitments have been pledged toward projects in the United States.
The Science Minister publicly accepted that the NHS had to invest a greater share on treatments, noting that its expenditure on drugs had declined as a proportion of its overall budget over the previous ten-year period.
